title: Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
source: Yahoo
date: 2025-10-20
url: https://finnhub.io/api/news?id=1e9dbaf41953c277f26e4ff578a8861bfff09a0cdfb19eb428566cf3bedcc0c4
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
